KURA

Kura Oncology (KURA)

Kura Oncology Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:KURA

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/21	07 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KURA	Kura Oncology Inc
2024/05/21	05 : 19	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:KURA	Kura Oncology Inc
2024/05/14	20 : 30	GlobeNewswire Inc.	Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML	NASDAQ:KURA	Kura Oncology Inc
2024/05/08	20 : 30	GlobeNewswire Inc.	Kura Oncology to Participate in Bank of America Securities Healthcare Conference	NASDAQ:KURA	Kura Oncology Inc
2024/05/03	20 : 30	GlobeNewswire Inc.	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:KURA	Kura Oncology Inc
2024/05/03	05 : 05	GlobeNewswire Inc.	Kura Oncology Reports First Quarter 2024 Financial Results	NASDAQ:KURA	Kura Oncology Inc
2024/04/25	20 : 30	GlobeNewswire Inc.	Kura Oncology to Report First Quarter 2024 Financial Results	NASDAQ:KURA	Kura Oncology Inc
2024/04/22	20 : 30	GlobeNewswire Inc.	Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	NASDAQ:KURA	Kura Oncology Inc
2024/04/10	20 : 30	GlobeNewswire Inc.	Kura Oncology to Participate in Stifel Targeted Oncology Forum	NASDAQ:KURA	Kura Oncology Inc
2024/04/05	20 : 30	GlobeNewswire Inc.	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:KURA	Kura Oncology Inc
2024/03/06	21 : 30	GlobeNewswire Inc.	Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	NASDAQ:KURA	Kura Oncology Inc
2024/03/02	07 : 00	GlobeNewswire Inc.	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:KURA	Kura Oncology Inc
2024/02/28	06 : 52	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:KURA	Kura Oncology Inc
2024/02/28	06 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KURA	Kura Oncology Inc
2024/02/28	06 : 01	GlobeNewswire Inc.	Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:KURA	Kura Oncology Inc
2024/02/26	21 : 30	GlobeNewswire Inc.	Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	NASDAQ:KURA	Kura Oncology Inc
2024/02/22	21 : 30	GlobeNewswire Inc.	Kura Oncology to Participate in Three Upcoming Investor Conferences	NASDAQ:KURA	Kura Oncology Inc
2024/02/20	21 : 30	GlobeNewswire Inc.	Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:KURA	Kura Oncology Inc
2024/02/16	06 : 01	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:KURA	Kura Oncology Inc
2024/02/15	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:KURA	Kura Oncology Inc
2024/02/15	07 : 58	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:KURA	Kura Oncology Inc
2024/02/14	07 : 23	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:KURA	Kura Oncology Inc
2024/02/10	07 : 21	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:KURA	Kura Oncology Inc
2024/02/02	21 : 30	GlobeNewswire Inc.	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:KURA	Kura Oncology Inc
2024/02/01	07 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KURA	Kura Oncology Inc
2024/02/01	07 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KURA	Kura Oncology Inc
2024/02/01	07 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KURA	Kura Oncology Inc
2024/02/01	07 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KURA	Kura Oncology Inc
2024/01/31	06 : 10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:KURA	Kura Oncology Inc
2024/01/30	21 : 08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KURA	Kura Oncology Inc